Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial

Anne Charlotte Teyssier; Hélène Lapillonne; Marlene Pasquet; Paola Ballerini; André Baruchel; Stephane Ducassou; Odile Fenneteau; Arnaud Petit; Wendy Cuccuini; Christine Ragu; Claude Preudhomme; Thomas Mercher; Nicolas Sirvent; Guy Leverger

doi:10.1080/08880018.2017.1414905

Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial

Anne Charlotte Teyssier, Hélène Lapillonne, Marlene Pasquet, Paola Ballerini, André Baruchel, Stephane Ducassou, Odile Fenneteau, Arnaud Petit, Wendy Cuccuini, Christine Ragu, Claude Preudhomme, Thomas Mercher, Nicolas Sirvent, Guy Leverger

Research output: Contribution to journal › Letter › peer-review

12 Citations (Scopus)

Abstract

We report the outcome of 27 children with de novo acute megakaryoblastic leukemia (AMKL) (excluding Down syndrome) enrolled in the French multicenter prospective study ELAM02 (2005-2011). There was no difference in gender, initial leukocyte count, CNS involvement, and complete remission rate (88.9%), as compared to other acute myeloid leukemia (AML) subtypes. AMKL patients had a significantly poorer outcome (5-year overall survival 54% [CI 95% 33%–71%] than children with other AML subtypes (5-year overall survival 73% [CI 95% 68%–77%] p = 0.02). Gender, age, CNS leukemia, hyperleukocytosis, complete remission or cytogenetic subgroups were not significant prognostic factors of disease-free survival. AMKL (excluding Down syndrom) remains an AML subgroup with inferior outcome.

Original language	English
Pages (from-to)	425-427
Number of pages	3
Journal	Pediatric Hematology and Oncology
Volume	34
Issue number	8
DOIs	https://doi.org/10.1080/08880018.2017.1414905
Publication status	Published - 17 Nov 2017

Keywords

AMKL
ELAM02
pediatric acute megakaryoblastic leukemia

Access to Document

10.1080/08880018.2017.1414905

Cite this

Teyssier, A. C., Lapillonne, H., Pasquet, M., Ballerini, P., Baruchel, A., Ducassou, S., Fenneteau, O., Petit, A., Cuccuini, W., Ragu, C., Preudhomme, C., Mercher, T., Sirvent, N., & Leverger, G. (2017). Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. Pediatric Hematology and Oncology, 34(8), 425-427. https://doi.org/10.1080/08880018.2017.1414905

@article{4cb93579a3294ca9b32d10f0ffb52647,

title = "Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial",

abstract = "We report the outcome of 27 children with de novo acute megakaryoblastic leukemia (AMKL) (excluding Down syndrome) enrolled in the French multicenter prospective study ELAM02 (2005-2011). There was no difference in gender, initial leukocyte count, CNS involvement, and complete remission rate (88.9%), as compared to other acute myeloid leukemia (AML) subtypes. AMKL patients had a significantly poorer outcome (5-year overall survival 54% [CI 95% 33%–71%] than children with other AML subtypes (5-year overall survival 73% [CI 95% 68%–77%] p = 0.02). Gender, age, CNS leukemia, hyperleukocytosis, complete remission or cytogenetic subgroups were not significant prognostic factors of disease-free survival. AMKL (excluding Down syndrom) remains an AML subgroup with inferior outcome.",

keywords = "AMKL, ELAM02, pediatric acute megakaryoblastic leukemia",

author = "Teyssier, {Anne Charlotte} and H{\'e}l{\`e}ne Lapillonne and Marlene Pasquet and Paola Ballerini and Andr{\'e} Baruchel and Stephane Ducassou and Odile Fenneteau and Arnaud Petit and Wendy Cuccuini and Christine Ragu and Claude Preudhomme and Thomas Mercher and Nicolas Sirvent and Guy Leverger",

note = "Publisher Copyright: {\textcopyright} 2017 Taylor & Francis Group, LLC.",

year = "2017",

month = nov,

day = "17",

doi = "10.1080/08880018.2017.1414905",

language = "English",

volume = "34",

pages = "425--427",

journal = "Pediatric Hematology and Oncology",

issn = "0888-0018",

number = "8",

}

Teyssier, AC, Lapillonne, H, Pasquet, M, Ballerini, P, Baruchel, A, Ducassou, S, Fenneteau, O, Petit, A, Cuccuini, W, Ragu, C, Preudhomme, C, Mercher, T, Sirvent, N & Leverger, G 2017, 'Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial', Pediatric Hematology and Oncology, vol. 34, no. 8, pp. 425-427. https://doi.org/10.1080/08880018.2017.1414905

TY - JOUR

T1 - Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial

AU - Teyssier, Anne Charlotte

AU - Lapillonne, Hélène

AU - Pasquet, Marlene

AU - Ballerini, Paola

AU - Baruchel, André

AU - Ducassou, Stephane

AU - Fenneteau, Odile

AU - Petit, Arnaud

AU - Cuccuini, Wendy

AU - Ragu, Christine

AU - Preudhomme, Claude

AU - Mercher, Thomas

AU - Sirvent, Nicolas

AU - Leverger, Guy

PY - 2017/11/17

Y1 - 2017/11/17

N2 - We report the outcome of 27 children with de novo acute megakaryoblastic leukemia (AMKL) (excluding Down syndrome) enrolled in the French multicenter prospective study ELAM02 (2005-2011). There was no difference in gender, initial leukocyte count, CNS involvement, and complete remission rate (88.9%), as compared to other acute myeloid leukemia (AML) subtypes. AMKL patients had a significantly poorer outcome (5-year overall survival 54% [CI 95% 33%–71%] than children with other AML subtypes (5-year overall survival 73% [CI 95% 68%–77%] p = 0.02). Gender, age, CNS leukemia, hyperleukocytosis, complete remission or cytogenetic subgroups were not significant prognostic factors of disease-free survival. AMKL (excluding Down syndrom) remains an AML subgroup with inferior outcome.

AB - We report the outcome of 27 children with de novo acute megakaryoblastic leukemia (AMKL) (excluding Down syndrome) enrolled in the French multicenter prospective study ELAM02 (2005-2011). There was no difference in gender, initial leukocyte count, CNS involvement, and complete remission rate (88.9%), as compared to other acute myeloid leukemia (AML) subtypes. AMKL patients had a significantly poorer outcome (5-year overall survival 54% [CI 95% 33%–71%] than children with other AML subtypes (5-year overall survival 73% [CI 95% 68%–77%] p = 0.02). Gender, age, CNS leukemia, hyperleukocytosis, complete remission or cytogenetic subgroups were not significant prognostic factors of disease-free survival. AMKL (excluding Down syndrom) remains an AML subgroup with inferior outcome.

KW - AMKL

KW - ELAM02

KW - pediatric acute megakaryoblastic leukemia

UR - http://www.scopus.com/inward/record.url?scp=85041424272&partnerID=8YFLogxK

U2 - 10.1080/08880018.2017.1414905

DO - 10.1080/08880018.2017.1414905

M3 - Letter

C2 - 29303660

AN - SCOPUS:85041424272

SN - 0888-0018

VL - 34

SP - 425

EP - 427

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

IS - 8

ER -

Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial

Abstract

Keywords

Access to Document

Other files and links

Cite this